FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

1411	ED 3	ואוי	SEC	OKI	IIES	WIAT .	, _^	CHA	NGE	CON	114113	SIU
				10/6	obinat	on D C	20540					

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre		Person*	2. Issuer Name and Ticker or Trading Symbol Singular Genomics Systems, Inc. [OMIC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) 3010 SCIENCE	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/12/2024	Director 10% Owner  Officer (give title Other (specify below)  Chief Executive Officer						
(Street) SAN DIEGO (City)	CA (State)	92121 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired Disposed of or Reneficially Owned										

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock	11/12/2024		M <sup>(1)</sup>		1,907	A	(1)	2,232	D			
Common Stock	11/12/2024		S		695(2)	D	\$22.545	1,537	D			
Common Stock	11/12/2024		G <sup>(3)</sup>		1,212	D	\$0	325	D			
Common Stock	11/12/2024		G <sup>(3)</sup>		1,212	A	\$0	141,487	I	By The Andrew K. Spaventa Living Trust dated April 9, 2014		
Common Stock								85	I	By Axon Holdings, LLC <sup>(4)</sup>		

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(5)	11/12/2024		М			1,907	(6)	(6)	Common Stock	1,907	\$0	24,780	D	

- 1. Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- 2. The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted RSUs.
- 3. Immediately upon settlement of the vested RSUs, and following the withholding described above, the Reporting Person transferred the shares as a gift to The Andrew K. Spaventa Living Trust dated April 9, 2014.
- 4. The shares are held directly by Axon Holdings, LLC. The managing member of Axon Holdings, LLC is Axon Managers, LLC. The Reporting Person is a managing member of Axon Managers, LLC and may be deemed to have shared voting and investment power over the shares held by Axon Holdings, LLC. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- 5. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- 6. The RSUs vest in 16 equal quarterly installments over four years measured from February 12, 2024.

/s/ Dalen Meeter, Attorney-in-**Fact** 

11/13/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.